A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients

NCT00592475 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Cirrhosis

Interventions

DRUG: conivaptan
DRUG: Placebo

Sponsor

Cumberland Pharmaceuticals